Inozyme Pharma, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Inozyme Pharma is focusing on its ENPP1 Deficiency program after reporting a net loss of $28.0 million for the first quarter of 2025.
10-Q: Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Clinical Program Update
Inozyme Pharma continues to advance its clinical trials for INZ-701, reporting positive interim data and progress across multiple programs.
10-Q: Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Program Update
Inozyme Pharma continues to advance its clinical trials for INZ-701, reporting positive data and anticipating key milestones in the development of treatments for rare diseases.
Inozyme Pharma's first quarter 2024 results highlight progress in clinical trials for INZ-701 and financial updates.